

AVANDIA[®] SIGNIFICANTLY REDUCES RISK OF PROGRESSION TO TYPE 2 DIABETES BY 62 PERCENT IN LARGEST-EVER DIABETES PREVENTION TRIAL¹

MISSISSAUGA, Canada – 15 September, 2006 – In the Canadian-led largest diabetes-prevention trial ever conducted worldwide, Avandia[®] (rosiglitazone maleate) tablets reduced the risk of developing type 2 diabetes by 62 percent relative to placebo among people at high risk of developing type 2 diabetes. This highly statistically significant reduction of 62 percent ($p < 0.0001$) was additive to standard counselling on healthy eating and exercise. The results of the landmark study are being reported today both in *The Lancet* and at the 42nd annual meeting of the European Association for the Study of Diabetes (EASD).¹

The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) trial evaluated the likelihood of progression to type 2 diabetes over a three-year median follow-up period among 5,269 people from 21 countries with a condition known as “pre-diabetes.”¹ In pre-diabetes, blood sugar levels are higher than normal, but not yet high enough for a diagnosis of type 2 diabetes.³ Canada had 51 DREAM trial sites involving 1,390 patients – representing over a quarter of the total number of patients involved worldwide. Patients included in the study were randomized to rosiglitazone (8 mg daily) or placebo and to ramipril (15 mg daily) or placebo and were assessed every six months for three to five years to determine if rosiglitazone or ramipril can reduce the risk of developing type 2 diabetes in pre-diabetic patients, when added to healthy eating and exercise counselling.¹ The DREAM study was not designed as a direct comparison between rosiglitazone and ramipril. Results from the ramipril arm of the study, which increased regression to normoglycemia but did not reduce the risk of diabetes or death, are also being reported at EASD and published separately in the *New England Journal of Medicine*.⁴

In this study, designed and conducted by the Population Health Research Institute at McMaster University, 10.6 percent of people receiving rosiglitazone progressed to type 2 diabetes versus 25 percent of people treated with placebo.¹ In the composite primary endpoint of development of diabetes or death from any cause, rosiglitazone demonstrated a 60 percent risk reduction relative to placebo ($p < 0.0001$).¹

“The DREAM findings are particularly significant as we are in the midst of an epidemic of type 2 diabetes with global implications. It is also noteworthy that the damaging complications of type 2 diabetes can often precede the diagnosis of this condition by several years,” said Dr. Bernard Zinman, DREAM Steering Committee Member, director of the Diabetes Centre, Mount Sinai Hospital and professor of medicine, University of Toronto, Canada. “By demonstrating that rosiglitazone significantly reduced the risk of developing type 2 diabetes, these data provide important evidence that it may be possible to alter the course of rising blood sugar levels and its consequences.”

Over the three-year median follow-up period of the trial, 51 percent of the people receiving rosiglitazone returned to normal blood sugar levels compared to 30 percent of people receiving placebo; thus, people taking rosiglitazone were about 70 percent ($p < 0.0001$) more likely than those taking placebo to return to normal blood sugar levels. As might be expected, people in the placebo group with higher Body Mass Index (BMI), an indicator of obesity, were more likely than those with lower BMI to progress to diabetes. However, the risk of developing diabetes did not increase with BMI in the group randomized to rosiglitazone. These findings suggest that rosiglitazone may reduce the increased risk of developing diabetes that is attributable to obesity.¹

“Type 2 diabetes is a complex, chronic disease that is most often managed by family physicians. With diabetes prevalence skyrocketing, we must identify aggressive screening and treatment strategies - that family physicians can easily implement in their practices – so that we can catch people at the greatest risk for type 2 diabetes early and curb this epidemic,” said Dr. Stewart Harris, Professor, Schulich School of Medicine and Dentistry, The University of Western Ontario in London and an investigator in the DREAM trial.

“What is exciting about the DREAM study is that it provides important information that will support the development of such strategies. Specifically, DREAM clearly suggests that a commonly prescribed type 2 diabetes medication that targets the underlying core defects of the disease – namely insulin resistance and beta cell dysfunction - may help delay and possibly disrupt the progression from pre-diabetes to type 2 diabetes. This is a major step forward in helping us better serve our patients.”

In the study, rosiglitazone was generally well tolerated. There was no significant difference between the rosiglitazone and placebo groups in withdrawal from study medication before study

end, or in the secondary composite endpoint of cardiovascular (CV) events that included myocardial infarction, stroke, CV death, confirmed heart failure, new angina and revascularization procedures (2.9 percent in the rosiglitazone group [75 events]; 2.1 percent in the placebo group [55 events], $p=0.15$). There was a low number of deaths in the trial and no significant difference between the two groups (1.1 percent in the rosiglitazone group [30 deaths] versus 1.3 percent in the placebo group [33 deaths], $p=0.7$). The most commonly reported CV event in the study was revascularization procedures. More events of confirmed heart failure were reported in people who received rosiglitazone as compared to those who received placebo (0.5 percent in people randomized to rosiglitazone [14 events] versus 0.1 percent in people randomized to placebo [2 events], $p=0.01$). Data presented by McMaster University showed that all cases of heart failure were treated effectively during the trial. Information about the potential for heart failure can be found in rosiglitazone prescribing information. At the conclusion of the study, mean bodyweight in the rosiglitazone group had increased slightly (2.2 kg) more than the placebo group.^{1,5}

Rosiglitazone belongs to the thiazolidinedione class of drugs and is an approved treatment for type 2 diabetes that improves blood sugar control, enabling people to reach recommended blood sugar levels. No agent including rosiglitazone is currently approved for the treatment of pre-diabetes.⁵

"The Canadian Diabetes Association Clinical Practice guidelines call for early screening and aggressive management of type 2 diabetes," said Donna Lillie, Vice President of Research and Professional Education at the Canadian Diabetes Association. "The DREAM study provides greater insight into addressing pre-diabetes patients at risk of experiencing the full onset of the condition. This is important because diabetes is a very serious and complex condition associated with devastating complications such as heart disease, kidney disease, adult blindness, and lower limb amputations. Obviously, the best way to prevent the serious complications of diabetes is to reduce the risk of diabetes in the first place. DREAM shows that this goal is within reach."

About the DREAM Study

DREAM is an international, multi-centre, randomized, double-blind, 2x2 factorial trial involving 5,269 patients from 21 countries with impaired glucose tolerance (IGT) and/or impaired fasting glucose (IFG), also known as pre-diabetes, who are therefore at high risk of developing type 2 diabetes. The DREAM study was conducted by the Population Health Research Institute at the

Michael G. DeGroot School of Medicine at McMaster University and Hamilton Health Sciences in Hamilton, Ontario. DREAM was funded by a peer-reviewed grant from the Canadian Institutes of Health Research (CIHR) via the CIHR/Rx&D Collaborative Research Program as well as by GlaxoSmithKline, sanofi-aventis and King Pharmaceuticals.¹

About Pre-diabetes and Type 2 Diabetes

The International Diabetes Federation (IDF) estimates a potential increase in pre-diabetes from 300 million people worldwide in 2003 to approximately 500 million by 2025.² While not everyone with pre-diabetes develops type 2 diabetes, large clinical outcomes trials have demonstrated that without intervention between 29 and 55 percent of people with pre-diabetes develop type 2 diabetes over the course of three years.⁶⁻⁸ As type 2 diabetes naturally progresses, the combined effects of core defects of the disease, namely insulin resistance and beta-cell dysfunction, can make it increasingly difficult for physicians to help patients control blood sugar levels.⁹

Pre-diabetes is considered a key stage in the development of type 2 diabetes – a chronic, progressive illness often linked to premature death that affects approximately 230 million individuals worldwide and is expected to affect 350 million people globally by 2025.^{3,10} Complications from diabetes can include eye disease, kidney disease, nerve damage, heart disease, stroke and peripheral vascular disease.¹¹⁻¹⁴ In fact, more than three million people die from diabetes-related causes each year – one death every 10 seconds.¹⁵

Important Information regarding Avandia (rosiglitazone maleate)

Rosiglitazone maleate (Avandia®) is indicated for use alone, or in combination with metformin or a sulfonylurea, to reduce insulin resistance and lower elevated blood sugar in patients with type 2 diabetes. Rosiglitazone directly targets insulin resistance and improves β -cell function, underlying causes of type 2 diabetes. The most common side effects reported in clinical trials with rosiglitazone were upper respiratory tract infection, headache, and back pain. Rosiglitazone is not for everyone. Rosiglitazone is not recommended for patients with severe heart failure or with serious liver disease.

About GlaxoSmithKline

GlaxoSmithKline – one of the world's leading research-based pharmaceutical and health-care companies – is committed to improving the quality of human life by enabling people to do more, feel better and live longer. In Canada, GSK is among the top 15 investors in research and

development, contributing more than \$140 million in 2004 alone. GSK is an Imagine Caring Company, and is consistently recognized as one of the 50 best companies to work for in Canada.

-30-

ATTENTION TELEVISION ASSIGNMENT/PRODUCERS

B-roll will be distributed via satellite feed at **2:00 – 2:30 p.m. EST on Friday, September 15, 2006.**

The satellite coordinates are as follows:

Anik F2 C
Transponder 3B
Audio subcarrier 6.2 and 6.8
Downlink frequency 3820 vertical

If you experience problems with the feed, please call CNW at (416) 863-2112.

For more information, or to schedule an interview with a Canadian DREAM investigator, please contact:

Peter Gay, Hill and Knowlton Canada
Office: 416-413-4732
Cell: 416-523-1420
peter.gay@hillandknowlton.ca

Julie Holroyde, Hill and Knowlton Canada
Office: 416-413-4625
Cell: 416-805-7942
julie.holroyde@hillandknowlton.ca

GlaxoSmithKline

Corporate Communications: 905-819-3363

References:

1. The DREAM (Diabetes Reduction Assessment with ramipril and rosiglitazone Medication) Trial Investigators. Effect of rosiglitazone on the frequency of diabetes in patients with impaired glucose tolerance or impaired fasting glucose: a randomized controlled trial. *The Lancet*. Published Online September 15, 2006. DOI:10.1016/S0140-6736(06)69420-8.
2. International Diabetes Federation. Fact Sheet: Impaired Glucose Tolerance (IGT). Available at: <http://www.idf.org/home/index.cfm?node=1224>. Accessed on August 3, 2006.
3. Gluco-Forum. What is pre-diabetes. Available at: <http://www.glucoforum.org/glucoforum/front/Controller?controller=InterligoController&action=loadPage&codeRubrique=10&codePage=31>. Accessed on August 3, 2006.
4. International Diabetes Federation. Fact Sheet: Impaired Glucose Tolerance (IGT). Available at: <http://www.idf.org/home/index.cfm?node=1224>. Accessed on August 3, 2006.
5. Avandia Prescribing Information
6. Gluco-Forum. Preventing diabetes. Available at: <http://www.glucoforum.org/glucoforum/front/Controller?controller=InterligoController&action=loadPage&codeRubrique=7>. Accessed on August 3, 2006.
7. Diabetes Prevention Program Research Group. Reduction in the Incidence of Type 2 Diabetes with Lifestyle Intervention or Metformin. *NEJM*. 2002;346:393-403.
8. [Ramachandran A](#), [Snehalatha C](#), Mary S, [Mukesh B](#), Bhaskar AD, Vijay V; [Indian Diabetes Prevention Programme \(IDPP\)](#). The Indian Diabetes Prevention Programme shows that lifestyle modification and metformin prevent type 2 diabetes in Asian Indian subjects with impaired glucose tolerance (IDPP-1). *Diabetologia*. 2006;49:289-297.

9. Gerich JE. Redefining the clinical management of type 2 diabetes: Matching therapy to pathophysiology. *Eur J Clin Invest.* 2002;32 (Supplement 3):46– 53.
10. Unite for Diabetes. The Global Epidemic of the 21st Century. Available at: http://www.unitefordiabetes.org/assets/files/About_diabetes.pdf. Accessed on August 16, 2006.
11. Molitch ME, DeFronzo RA, Franz MJ, *et al.* Diabetic nephropathy. *Diabetes Care.* 2003;26 (Supplement 1):S94–S98.
12. Fong DS, Aiello L, Gardner TW, *et al.* Diabetic retinopathy. *Diabetes Care.* 2003;26 (Supplement 1):S99–S102.
13. Mayfield JA, Reiber GE, Sanders LJ, *et al.* Preventive foot care in people with diabetes. *Diabetes Care.* 2003;26 (Supplement 1):S78–S79.
14. Kannel WB, D'Agostino RB, Wilson PW, *et al.* Diabetes, fibrinogen, and risk of cardiovascular disease: the Framingham experience. *Am Heart J.* 1990;120:672–676.
15. International Diabetes Federation. Did You Know? Available at: <http://www.idf.org/home/index.cfm?unode=3B96906B-C026-2FD3-87B73F80BC22682A>. Accessed on August 3, 2006.